Avecho Biotechnology Limited

ASX:AVE Stock Report

Market Cap: AU$9.5m

Avecho Biotechnology Past Earnings Performance

Past criteria checks 0/6

Avecho Biotechnology's earnings have been declining at an average annual rate of -19.8%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been declining at an average rate of 36.5% per year.

Key information

-19.8%

Earnings growth rate

-14.4%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate-36.5%
Return on equity-53.9%
Net Margin-725.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

May 31
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Nov 04
Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Mar 23
We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Dec 08
We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Revenue & Expenses Breakdown

How Avecho Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:AVE Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-321
30 Sep 231-431
30 Jun 231-431
31 Mar 231-331
31 Dec 221-221
30 Sep 221-221
30 Jun 221-231
31 Mar 221-331
31 Dec 211-331
30 Sep 211-331
30 Jun 210-331
31 Mar 210-330
31 Dec 200-330
30 Sep 200-220
30 Jun 200-220
31 Mar 202-120
31 Dec 194120
30 Sep 194120
30 Jun 195030
31 Mar 193-230
31 Dec 181-440
30 Jun 181-661
31 Mar 181-771
31 Dec 171-981
30 Jun 171-1681
31 Mar 171-1781
31 Dec 162-1782
30 Sep 162-1792
30 Jun 163-1792
31 Mar 162-1892
31 Dec 152-2092
30 Sep 152-1782
30 Jun 153-1473
31 Mar 152-1063
31 Dec 142-763
30 Jun 141-763
31 Mar 141-973
31 Dec 131-1174
30 Sep 131-1293
30 Jun 131-1183

Quality Earnings: AVE is currently unprofitable.

Growing Profit Margin: AVE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AVE is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.

Accelerating Growth: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).


Return on Equity

High ROE: AVE has a negative Return on Equity (-53.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.